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As of mid-March, 2020, many countries in the world are on partial lockdown, to control the spread of the 
pandemic (COVID-19) resulting from the SARS-CoV-2 coronavirus.  The only effective ‘treatments’ at 
this time are good hygiene and quarantine.  This document presents a novel combined tactical and 
strategic treatment approach for COVID-19 that incorporates both the tactical and strategic approaches 
we have developed for preventing and reversing myriad diseases, including treatment repurposing as well.  
Optimally, the tactical and strategic approach components would be implemented in parallel, to provide 
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INTRODUCTION 
Background 
Over the past two decades, there have been at least three major coronavirus-based infectious 
disease outbreaks/epidemics/pandemics: Severe Acute Respiratory Syndrome (SARS), 2002-2003; 
Middle East Respiratory Syndrome (MERS), starting in 2012; COVID-19, starting in December 2019.  
There are a number of similarities among these three infectious diseases, including abnormal values of 
selected biomarkers (e.g., neutrophils, lymphocytes, albumin, CRP, TNF-alpha, etc), pulmonary 
inflammation, pulmonary damage, and the demographic affected most severely (elderly, with co-
morbidities, and others with weakened immune systems) [1-6]. 
There are also similarities of COVID-19 with influenza: “Both [COVID-19 and influenza] cause 
fever, cough, body aches and fatigue; sometimes vomiting and diarrhea; can be mild or severe, even fatal 
in rare cases; can result in pneumonia” (https://www.hopkinsmedicine.org/health/conditions-and-
diseases/coronavirus/coronavirus-disease-2019-vs-the-flu).  Additionally, “Neither virus is treatable with 
antibiotics, which only work on bacterial infections; both are treated by addressing symptoms, such as 
reducing fever; severe cases may require hospitalization and support such as mechanical ventilation”. 
One major difference between COVID-19 and influenza is the number of fatalities.  According to 
the above link (and other supporting references), for influenza, the estimate is “1 billion cases worldwide; 
9.3 million to 45 million cases in the U.S. per year”, accompanied by “291,000 to 646,000 deaths 
worldwide; 12,000 to 61,000 deaths in the U.S. per year”.  For the previous coronavirus-based 
outbreaks/epidemics/pandemics, these cases/fatalities numbers have been orders of magnitude less than 
the influenza numbers.  The SARS pandemic involved about 8,000 people who presented with SARS 
symptoms, of whom ~800 died [7, 8].  The MERS epidemic involved ~2500 cases, and almost 900 deaths 
(http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-
2020.html). As of 21 March 2020, for COVID-19 there are “Approximately 11,906 deaths reported 
worldwide; 260 deaths in the U.S.”, according to the Hopkins link above. 
The main measures being taken to control the spread of the SARS-CoV-2 coronavirus 
(responsible for COVID-19) are conceptually those that were taken to control the spread of the SARS-
CoV coronavirus in 2002-2003: good hygiene and quarantine.  The difference is the scale of these 
measures.  Currently, many countries are on partial lockdown, restricting many activities and businesses 
that involve gatherings of large numbers of people in close proximity.  It is unknown how long these 
restrictions will be in place. 
Probably the best datapoint on the effectiveness of these stringent measures is that of China, 
where the current SARS-CoV-2-based infectious disease seems to have started in December 2019.  
According to Worldometers (https://www.worldometers.info/coronavirus/), which contains country data 
as well as global data, China has experienced about 75,000 COVID-19 cases and 3300 deaths, as of 21 
March 2020.  The time curve of China’s deaths has essentially flattened by early-to-mid March, 
approximately six weeks since the initial rise of cases and deaths.  Compare these COVID-19 death 
statistics in China with those of influenza.  According to the following reference 
(https://championtraveler.com/news/the-us-flu-season-is-bad-this-year-but-influenza-is-still-way-more-
deadly-around-the-world/), China averages about 200,000 influenza-associated deaths per year.  So, if the 
China COVID-19 death statistics plot is a true flattening currently, rather than an inflection point, then 
China’s COVID-19-associated deaths (~3300) will be ~1.5% of their average annual influenza-associated 
deaths (~200,000).   
Potential COVID-19 Treatments 
Because of uncertainties as to the extent and duration of COVID-19 global spread, myriad 
treatments are being pursued in parallel.  Work on vaccines is being accelerated 
(https://www.fiercebiotech.com/biotech/biopharma-s-no-holds-barred-fight-to-find-a-covid-19-vaccine-
full-list), although widescale implementation is estimated to take perhaps eighteen months or more, 
assuming positive development results.  Treatments being investigated for the interim include potential 
repurposed treatments such as remdesivir, chloroquine, hydroxychloroquine, azithromycin, etc 
(https://techcrunch.com/2020/03/20/hydroxychloroquine-chloroquine-and-other-potential-covid-19-
treatments-explained/).  These repurposed treatments are treatments that have been developed for, and 
applied to, other diseases, and offer the promise of applicability to COVID-19 as well. 
Over the past decade+, our research group has been developing protocols for preventing and 
reversing diseases.  These protocols consist of identifying both tactical and strategic treatments (defined 
in the Methodology section), using different methods to identify these tactical and strategic treatments.  In 
all cases examined, we have identified voluminous amounts of both existing and novel tactical and 
strategic treatments.  In this period of the global COVID-19 crisis, is it possible to integrate our separate 
treatment identification methodologies into one comprehensive and streamlined approach for both 
reactively treating COVID-19 in the short-term and proactively strengthening the immune system to 
reduce susceptibility to similar infections in the long-term?  I believe it is, and present the combined 




The proposed approach integrates our strategic and tactical treatment approaches.  It essentially 
broadens the tactical treatment approach into covering both prevention and treatment.  A summary of the 
protocol we have developed for preventing and reversing diseases, including potential application to three 
specific chronic diseases [9-11], is contained in Reference [12].  A recent updated expansion of our 
tactical approach used mainly for treatment repurposing, including examples of results from myriad 
diseases using an earlier version of the treatment repurposing approach [7, 13-16], is presented in 
Reference [17]. 
The proposed integrated approach is as follows.  Perform a survey of the relevant literature for 
the disease of interest (COVID-19, MERS, SARS, etc, in the present case).  Identify those biomarkers 
that show abnormal levels, and identify undesirable symptoms as well.  Identify the directions of change 
desired for the biomarkers and symptoms in order to return to normality.  Use this information differently 







The details of the crucial step for identifying treatments depend on whether the desired treatment 
is tactical or strategic, and completing this step fully requires a broadened definition of treatments.  If 
treatments are defined as a set of actions that improve health, then (at least) two types of treatments are 
possible.  The first can be defined as positive treatments.  These are the classical treatments where drugs 
and/or radiation and/or surgery are implemented, and symptoms are alleviated.  These positive treatments 
are basically a reactive tactical response to abnormal markers of health.  They can be applied for the 
short-term (e.g., antibiotics for bacterial infections, antivirals for viral infections, etc), or for the long-term 
(e.g., statins, blood thinners, antihypertensives, etc).  The second can be defined as negative-negative 
treatments, where those factors that contribute to disease are first identified and then removed.  The name 
derives from the mathematics world, where a negative of a negative is a positive.  These negative-
negative treatments are basically a proactive strategic response to abnormal markers of health, and 
typically involve long-term changes in lifestyle and harmful exposures for improved health.   
Tactical Treatments 
The proposed approach integrates tactical and strategic treatments.  For the tactical treatments, 
select the most important biomarkers identified, the direction of change desired for each biomarker, and 
combine these biomarkers and desired directions of change into a query.  For example, in the case of 
COVID-19, assume positive treatment outcomes would result from the following: increase albumin, 
lymphocytes; decrease CRP, IL-6, IL-1beta [1-6].  Combine these biomarkers and directions of change 
into a query; there are many ways to do this.  One option is a query consisting of all combinations of two 
biomarkers (e.g., one term in the query might be “increase albumin AND decrease CRP”) from the pool 
of important biomarkers identified.  Another option is a query consisting of all combinations of three 
biomarkers, and so on.  Queries actually employed are shown in detail in Reference [17].  If both existing 
and repurposed tactical treatments are desired, use the query to search all of Medline.  For (mainly) 
tactical treatment repurposing only, search all of Medline except for the core literature that defines the 
disease of interest (in the present case, the COVID-19, MERS, SARS, etc, literature).  The detailed 
approach to achieve treatment repurposing only is also discussed in Reference [17].   
After the query has been entered into the Medline search engine, the retrieved records are 
examined for existing and/or novel treatments (depending on objectives), and the most promising are 
selected for further evaluation.  Many of the records will contain far more biomarkers and their directions 
of change than were contained in the query term that retrieved those specific records.  For treatment 
repurposing, one criterion for prioritizing these retrieved candidates is the number of biomarkers in the 
record that change in the desired directions.  Other prioritization criteria are used as well [13-17]. 
Strategic Treatments 
For the strategic treatments, select the important biomarkers identified as above, and the direction 
of change desired for each biomarker.  Reverse the desired directions of change.  Combine these 
biomarkers and new directions of change in a query.  For the biomarkers assumed for the COVID-19 case 
in the previous tactical section, the example query term would now read “decrease albumin AND 
increase CRP”.  If queries with such terms are used to search all of Medline, they would retrieve many 
records identifying existing and potential contributing factors to the disease of interest.  Once these 
contributing factors have been identified, their proactive strategic removal would then be recommended.  
If only novel contributing factors (those not found in the disease core literature) are desired, then, as for 
the case of repurposed treatments, all of Medline would be searched except for the core literature that 
defines the disease of interest (in the present case, the COVID-19, MERS, SARS, etc, literature). 
Reactive vs Strategic Treatments 
The reactive tactical treatment approach for countering infections from viral exposure improves 
biomarker levels and reduces symptoms (if successful), but ordinarily does little to improve the body’s 
resistance to disease.  For viral infections, the tactical treatments will do little to strengthen the weakened 
immune system.  As a result, people with weakened immune systems will again be vulnerable to infection 
from exposure to the next harmful virus they encounter. 
The proactive strategic treatment approach will strengthen the immune (and other) systems by 
removing those critical factors that contribute to disease and a weakened immune system (unless 
irreversible damage has been done or individuals have a strong genetic predisposition to disease).  These 
strategic treatments tend to require long-term adherence by their recipients.  In turn, these recipients of 
strategic treatments will be less vulnerable to infection from exposure to the next harmful virus they 
encounter.  Like many healthy people who were exposed to SARS-CoV and SARS-CoV-2, these people 
who follow the (typically) long-term proactive strategic treatment regimen successfully may not even be 
aware they have been exposed to the coronavirus.  The only indication of their exposure will be 
coronavirus antibodies in their serum. 
 
 
CONCLUSIONS AND RECOMMENDATIONS 
This document has presented an integrated tactical and strategic treatment approach for COVID-
19 in particular, and any infectious disease in general.  It is recommended that both the tactical and 
strategic treatments be implemented in parallel.  The tactical treatments might allow the vulnerable to 
survive the near-term potentially lethal effects of SARS-CoV-2 viral exposure, and the strategic 
treatments will allow them to be more resistant to future viral attacks of all types. 
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